

September 2, 2022

Ying Huang, Ph.D
Chief Financial Officer
Legend Biotech Corporation
2101 Cottontail Lane
Somerset, NJ 08873

Re: Legend Biotech
Form 20-F for
Filed March 31,
File No. 001-39307

Corporation

Fiscal Year Ended December 31, 2021
2022

Dear Dr. Huang:

We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Form 20-F for Fiscal Year Ended December 31, 2021

Certain Information, page 1

1. We note that your definition of China or PRC specifically excludes Hong Kong and Macau. Please revise the definition of China or the PRC to include Hong Kong and Macau and clarify that the only time that "PRC or China" does not include Hong Kong or Macau is when you reference specific laws and regulations adopted by the PRC. Additionally, clarify that the legal and operational risks associated with operating in China also apply to operations in Hong Kong and Macau. Lastly, discuss any commensurate laws and regulations in Hong Kong and Macau, where applicable throughout your filing, and the risks and consequences to you associated with those laws and regulations.

Ying Huang, Ph.D
FirstName LastNameYing Huang, Ph.D
Legend Biotech Corporation
Comapany 2,
September NameLegend
2022 Biotech Corporation

September
Page 2 2, 2022 Page 2
FirstName LastName
D. Risk Factors
Risk Factors Summary, page 4

2. Please revise your summary of risk factors so that you disclose the risks that your corporate structure and being based in or having the majority of the company s operations in China poses to investors is prominent and upfront. In particular, describe the significant regulatory, liquidity, and enforcement risks. For example, specifically discuss risks arising

from the legal system in China, including risks and uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with little advance notice; and the risk that the Chinese government may intervene or influence your operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in your operations and/or the value of your securities. Acknowledge any risks that any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of your securities to decline or be worthless.

Part I
Item 3. Key Information, page 4

3. At the onset of Part I, please disclose prominently that you are not a Chinese operating company but a Cayman Islands holding company with operations conducted by your subsidiaries. In addition, please provide early in the Business section a diagram of the company's corporate structure.

4. Provide prominent disclosure about the legal and operational risks associated with being based in or having the majority of the company's operations in China. Your disclosure should make clear whether these risks could result in a material change in your operations and/or the value of your securities or could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. Your disclosure should address how recent statements and regulatory actions by China's government, such as those related to data security or anti-monopoly concerns, have or may impact the company's ability to conduct its business, accept foreign investments, or list on a U.S. or other foreign exchange.

5. We note that, on May 4, 2022, the SEC conclusively listed you under the Holding Foreign Companies Accountable Act. Please provide prominent disclosure that your auditor is subject to the determinations announced by the PCAOB on December 16, 2021 and how the Holding Foreign Companies Accountable Act and related regulations will affect your company. In addition, disclose that trading in your securities may be prohibited under the Holding Foreign Companies Accountable Act if the PCAOB determines that it cannot

Ying Huang, Ph.D
FirstName LastNameYing Huang, Ph.D
Legend Biotech Corporation
Comapany 2,
September NameLegend
2022 Biotech Corporation

September
Page 3 2, 2022 Page 3
FirstName LastName

inspect or investigate completely your auditor, and that as a result an exchange may determine to delist your securities. For additional information, refer to <https://www.sec.gov/hfcaa>.

6. Clearly disclose how you will refer to the holding company and subsidiaries when providing the disclosure throughout the document so that it is clear to investors which entity the disclosure is referencing and which subsidiaries or entities are conducting the

business operations. For example, disclose, if true, that your subsidiaries conduct operations in China.

7. Provide a clear description of how cash is transferred through your organization. Disclose your intentions to distribute earnings. Quantify any cash flows and transfers of other assets by type that have occurred between the holding company and its subsidiaries, and direction of transfer. Quantify any dividends or distributions that a subsidiary have made to the holding company and which entity made such transfer, and their tax consequences. Similarly quantify dividends or distributions made to U.S. investors, the source, and their tax consequences. Your disclosure should make clear if no transfers, dividends, or distributions have been made to date. Describe any restrictions on foreign exchange and your ability to transfer cash between entities, across borders, and to U.S. investors. Describe any restrictions and limitations on your ability to distribute earnings from the company, including your subsidiaries, to the parent company and U.S. investors.

8. Disclose each permission or approval that you or your subsidiaries are required to obtain from Chinese authorities to operate your business and to offer securities to foreign investors. State whether you or your subsidiaries are covered by permissions requirements from the China Securities Regulatory Commission (CSRC), Cyberspace Administration of China (CAC) or any other governmental agency that is required to approve your operations, and state affirmatively whether you have received all requisite permissions or approvals and whether any permissions or approvals have been denied. Please also describe the consequences to you and your investors if you or your subsidiaries: (i) do not receive or maintain such permissions or approvals, (ii) inadvertently conclude that such permissions or approvals are not required, or (iii) applicable laws, regulations, or interpretations change and you are required to obtain such permissions or approvals in the future.

Risks Related to Doing Business in China, page 57

9. Given the Chinese government's significant oversight and discretion over the conduct of your business, please revise to highlight separately the risk that the Chinese government may intervene or influence your operations at any time, which could result in a material change in your operations and/or the value of your securities. Also, given recent statements by the Chinese government indicating an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, acknowledge the risk that any such action could significantly limit

Ying Huang, Ph.D
Legend Biotech Corporation
September 2, 2022
Page 4

or completely hinder your ability to offer or continue to offer securities to investors and cause the value of your securities to significantly decline or be worthless. The audit report included in this Annual Report is prepared by an auditor who is not inspected by the Public Company Accounting. . . , page 69

10. Update your disclosure to reflect that the Commission adopted rules to implement the HFCAA and that, pursuant to the HFCAA, the PCAOB has issued its report notifying the Commission of its determination that it is unable to inspect or

investigate completely
accounting firms headquartered in mainland China or Hong Kong. Moreover,
please
update this risk factor to account for the fact that the SEC
conclusively identified you
under the HFCAA on May 4, 2022.
Operating And Financial Review And Prospects
Operating Results, page 153

11. Please expand in future filings to include a more robust disclosures for
your operating
result, including more disaggregated disclosures about the significant
components of
revenues or expenses and their change drivers, both quantitatively and
qualitatively. More
specifically on the research and development expenses, considering the
significant
balances, the existence of other phase 3 trials, as well as the impact
from the Janssen
agreement, please provide more disaggregated disclosures by product
(group), and or by
nature of costs. Please also disclose specifically the amount of
research and
development expenses incurred by yourself as well as the amount payable
to Janssen
under your license and collaboration agreement with Janssen. In that
regard, you disclosed
at page F-49 that you took a total of \$119.7 million funding advances in
2021 by reducing
the same amount of other payables due to the collaborator. Refer to Item
303 of
Regulation S-K.

We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

You may contact Li Xiao at 202-551-4391 or Daniel Gordon at 202-551-3486
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Dillon Hagius at 202-551-7967 or Jason Drory at 202-551-8342 with any other
questions.

FirstName LastNameYing Huang, Ph.D
Corporation Finance
Comapany NameLegend Biotech Corporation
Sciences
September 2, 2022 Page 4
cc: Marc L. Harrison
FirstName LastName

Sincerely,
Division of
Office of Life